| Title: |
The Impact of Intraocular Treatment on Visual Acuity of Patients Diagnosed with Branch Retinal Vein Occlusions |
| Authors: |
Diana-Maria Darabuş; Mihnea Munteanu; Maria-Alexandra Preda; Olimpiu Ladislau Karancsi; Marius Cristian Șuță |
| Source: |
Healthcare, Vol 11, Iss 10, p 1414 (2023) |
| Publisher Information: |
MDPI AG |
| Publication Year: |
2023 |
| Collection: |
Directory of Open Access Journals: DOAJ Articles |
| Subject Terms: |
visual impairment; Ozurdex; retinal ischemia; macular edema; aflibercept; intraocular treatment; Medicine |
| Description: |
Branch retinal vein occlusions are a significant cause of vision loss and present several ophthalmic and systemic risk factors, including age, hypertension, hyperlipidemia and glaucoma. Retinal vein occlusion is the second-most-common retinal vascular disease. This study evaluated the effects of Ozurdex in contrast to a combination therapy with anti-vascular endothelial growth factor (VEGF) and cortisone in treatment-naive branch retinal vein occlusions-macular edema (BRVO-ME) cases, at 4-month and 6-month follow-ups. Thirty eyes were included in the study, which were divided into two groups. The first group consisted of 15 eyes, and each received 1 injection of dexamethasone intravitreal implant Ozurdex (DEX). The second group of 15 eyes received 3 intravitreal injections, the first and second with the anti-vascular endothelial growth factor aflibercept and the third one with 4 mg of triamcinolone acetonide (Vitreal S), spaced at one month. The best corrected visual acuity (BCVA) results suggested that the peak efficacy was at 4 months for both groups, with mean values of 0.5 LogMAR and 0.4 LogMAR. Regarding macular edema, there were no significant changes between the 4- and 6-month follow-up periods, with mean values of 361 μm and 390 μm. Six patients experienced transient raised intraocular pressure at one week after treatment. This study highlights the benefits to visual acuity of the combination of anti-vascular endothelial growth factor and cortisone, which represents a viable solution with similar results to Ozurdex therapy. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
https://www.mdpi.com/2227-9032/11/10/1414; https://doaj.org/toc/2227-9032; https://doaj.org/article/bd2e9aa979d246ee8a800ba5f1597089 |
| DOI: |
10.3390/healthcare11101414 |
| Availability: |
https://doi.org/10.3390/healthcare11101414; https://doaj.org/article/bd2e9aa979d246ee8a800ba5f1597089 |
| Accession Number: |
edsbas.ED6C87F5 |
| Database: |
BASE |